We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Tenet Healthcare Corp. is an investor-owned health care services company, which owns and operates general hospitals and related health care facilities for urban and rural communities in numerous states, and has offices in California and Florida. The company has investments in other health care companies and is one of the largest investor-owned health care delivery systems in the United States. Tenet Healthcare and its subsidiaries provide healthcare services primarily through general hospitals and related healthcare facilities. Its hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies; intensive care, critical and coronary care units; physical therapy along with orthopedic, oncology, and outpatient services. The related health care facilities include rehabilitation hospitals, specialty hospitals and long-term care facilities.
- Recent THC Stock Price: $88.09
- Yearly Gain for THC stock: 55.91%
- Market Cap for THC stock: $8.95B
- P/E Ratio for THC stock: 20.11
Will THC's stock price go up? Is there an accurate THC stock forecast available?
TipRanks.com reports that Tenet Healthcare Corporation currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $103.60. The target pricing ranges from a high THC forecast of $109 down to a low forecast of $100. Tenet Healthcare Corporation (THC)’s last closing stock price was $88.09 which would put the average price target at 17.61% upside.
In addition, TradingView issued a buy rating for THC stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on THC stock.
Other analysts covering THC include:
- Ann Hynes of Mizuho Securities issued a Buy rating with the price target of $100 on 20 hours ago
- Pito Chickering of Deutsche Bank issued a Buy rating with the price target of $100 on 20 hours ago
- Ben Hendrix of RBC Capital issued a Buy rating with the price target of $109 on 20 hours ago
- Jason Cassorla of Citi issued a Buy rating with the price target of $104 on 20 hours ago
If you are wondering if THC is a good stock to buy, here are 3rd party ratings for THC stock:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 12% (31 out of 250)
What is the sentiment on the street regarding Tenet Healthcare Corporation? (Current ratings compiled by TipRanks.com)
- News Sentiment for THC stock: Bullish
- Blogger Consensus for THC stock: {Blogger Consensus}
- Media Buzz for THC stock: Strong Buy
- Insider Signal for THC stock: Selling
- Investor Sentiment for THC stock: Positive
- Hedge Fund signal for THC stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on THC stock including scouring the social networks like THC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for THC stock chart >>
Summary: Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
- Recent ILMN Stock Price: $137.84
- Yearly Gain for ILMN stock: -29.62%
- Market Cap for ILMN stock: $21.89B
- P/E Ratio for ILMN stock: -19.41
Will ILMN's stock price go up? Is there an accurate ILMN stock forecast available?
TipRanks.com reports that Illumina, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $140.20. The target pricing ranges from a high ILMN forecast of $85 down to a low forecast of $135. Illumina, Inc. (ILMN)’s last closing stock price was $137.84 which would put the average price target at 1.71% upside.
In addition, TradingView issued a sell rating for ILMN stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ILMN stock.
Other analysts covering ILMN include:
- Patrick B Donnelly of Citi issued a Hold rating with the price target of $145 on 20 hours ago
- David Westenberg of Piper Sandler issued a Buy rating with the price target of $190 on 20 hours ago
- Rachel Vatnsdal of J.P. Morgan issued a Hold rating with the price target of $135 on 20 hours ago
- Luke Sergott of Barclays issued a Sell rating with the price target of $85 on 20 hours ago
If you are wondering if ILMN is a good stock to buy, here are 3rd party ratings for ILMN stock:
- TipRanks.com: Hold
- TradingView.com: sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 41% (103 out of 250)
What is the sentiment on the street regarding Illumina, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ILMN stock: Bullish
- Blogger Consensus for ILMN stock: {Blogger Consensus}
- Media Buzz for ILMN stock: Neutral
- Insider Signal for ILMN stock: Selling
- Investor Sentiment for ILMN stock: Negative
- Hedge Fund signal for ILMN stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on ILMN stock including scouring the social networks like ILMN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ILMN stock chart >>
Summary: Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
- Recent ZBH Stock Price: $122.80
- Yearly Gain for ZBH stock: -4.28%
- Market Cap for ZBH stock: $25.64B
- P/E Ratio for ZBH stock: 57.38
Will ZBH's stock price go up? Is there an accurate ZBH stock forecast available?
TipRanks.com reports that Zimmer Biomet Holdings, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $132.80. The target pricing ranges from a high ZBH forecast of $155 down to a low forecast of $109. Zimmer Biomet Holdings, Inc. (ZBH)’s last closing stock price was $122.80 which would put the average price target at 8.14% upside.
In addition, TradingView issued a Neutral rating for ZBH stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ZBH stock.
Other analysts covering ZBH include:
- Jeff Johnson of Robert W. Baird issued a Buy rating with the price target of $155 on 20 hours ago
- Robbie Marcus of J.P. Morgan issued a Hold rating with the price target of $125 on 20 hours ago
- Danielle Antalffy of UBS issued a Sell rating with the price target of $109 on 20 hours ago
- Pito Chickering of Deutsche Bank issued a Hold rating with the price target of $140 on 20 hours ago
If you are wondering if ZBH is a good stock to buy, here are 3rd party ratings for ZBH stock:
- TipRanks.com: Hold
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Bottom 31% (172 out of 250)
What is the sentiment on the street regarding Zimmer Biomet Holdings, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ZBH stock: Bullish
- Blogger Consensus for ZBH stock: {Blogger Consensus}
- Media Buzz for ZBH stock: Buy
- Insider Signal for ZBH stock: Selling
- Investor Sentiment for ZBH stock: Negative
- Hedge Fund signal for ZBH stock: Low Risk
The stock market is extremely volatile, and you need to do your own research on ZBH stock including scouring the social networks like ZBH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ZBH stock chart >>
Summary: McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
- Recent MCK Stock Price: $501.35
- Yearly Gain for MCK stock: 38.36%
- Market Cap for MCK stock: $66.71B
- P/E Ratio for MCK stock: 22.64
Will MCK's stock price go up? Is there an accurate MCK stock forecast available?
TipRanks.com reports that McKesson Corporation currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $557.20. The target pricing ranges from a high MCK forecast of $575 down to a low forecast of $505. McKesson Corporation (MCK)’s last closing stock price was $501.35 which would put the average price target at 11.14% upside.
In addition, TradingView issued a Strong buy rating for MCK stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MCK stock.
Other analysts covering MCK include:
- Kevin Caliendo of UBS issued a Buy rating with the price target of $575 on 20 hours ago
- Elizabeth Anderson CFA of Evercore ISI issued a Buy rating with the price target of $560 on 1 day ago
- Stephanie Davis of Barclays issued a Buy rating with the price target of $571 on 1 day ago
- Daniel Grosslight of Citi issued a Buy rating with the price target of $575 on 2 days ago
If you are wondering if MCK is a good stock to buy, here are 3rd party ratings for MCK stock:
- TipRanks.com: Buy
- TradingView.com: Strong buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 32% (79 out of 250)
What is the sentiment on the street regarding McKesson Corporation? (Current ratings compiled by TipRanks.com)
- News Sentiment for MCK stock: Bearish
- Blogger Consensus for MCK stock: {Blogger Consensus}
- Media Buzz for MCK stock: Strong Buy
- Insider Signal for MCK stock: Balanced
- Investor Sentiment for MCK stock: Positive
- Hedge Fund signal for MCK stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on MCK stock including scouring the social networks like MCK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MCK stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
